Kalpana Reddy, MD
Endocrinology, Diabetes & Metabolism · Flushing, NYNPI 1376647701
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $417,914 of the $470,124 with a category attached, or 88.9%. 42 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,275 payments — averaging $368.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$120K
- Boehringer Ingelheim$78K
- AstraZeneca$69K
- Mannkind Corporation$60K
- Sanofi-aventis U.S. LLC$48K
- Lilly USA, LLC$25K
- plus $70K from 36 others
What the payments were for
- Consulting fees$6,1631%
- Speaking & faculty fees$417,91489%
- Travel & lodging$6,9311%
- Food & beverage$38,9378%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$101,060
- FARXIGA$65,610
- Ozempic$58,767
- RYBELSUS$49,573
- AFREZZA$40,383
- SOLIQUA 100/33$31,849
- V-GO$25,471
- CeQur Simplicity$19,022
- Pogo Automatic Blood Glucose Monitoring System$16,236
- TOUJEO$12,581
- INVOKANA$9,591
- Kerendia$5,358
- DISEASE STATE$2,321
- BYDUREON$2,200
- iLet Bionic Pancreas$1,950
- iLet Insulin Infusion Kit Inset$531
- iLet Insulin Infusion Kit Contact Detach$531
- RAYOS$371
- DEXCOM G6 TRANSMITTER$335
- TEPEZZA$261
How this compares
$470,124 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,350 | $1,484,268 |
| JardianceEmpagliflozin | 992 | $769,018 |
| AfrezzaInsulin Regular, Human | 352 | $737,267 |
| FarxigaDapagliflozin Propanediol | 668 | $469,364 |
| MounjaroTirzepatide | 222 | $302,746 |
| TrulicityDulaglutide | 229 | $260,687 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 327 | $144,877 |
| JanuviaSitagliptin Phosphate | 187 | $131,009 |
| KerendiaFinerenone | 152 | $125,705 |
| RybelsusSemaglutide | 94 | $120,935 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 413 | $106,306 |
| JanumetSitagliptin Phos/Metformin Hcl | 129 | $86,237 |
| NovologInsulin Aspart | 382 | $75,001 |
| Tresiba Flextouch U-100Insulin Degludec | 154 | $68,503 |
| Novolog FlexpenInsulin Aspart | 419 | $58,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $119,500 | $1,689,9501,838 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Jentadueto | $78,211 | $850,3271,096 claims |
| Mannkind CorporationAfrezza | $60,298 | $737,267352 claims |
| Lilly USA, LLCMounjaro, Trulicity | $25,098 | $563,434451 claims |
| AstraZenecaFarxiga | $69,141 | $469,364668 claims |
| MerckJanuvia, Janumet | $621 | $217,246316 claims |
| Cequr CorporationCequr Simplicity | $19,022 | $144,877327 claims |
| BayerKerendia | $5,877 | $125,705152 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,160 | $69,63833 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $47,936 | $33,51237 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $314 | $9,58418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Flushing
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.